
Alana Harris Dent
Examiner (ID: 7014)
| Most Active Art Unit | 1643 |
| Art Unit(s) | 1643, 1642 |
| Total Applications | 1512 |
| Issued Applications | 526 |
| Pending Applications | 351 |
| Abandoned Applications | 660 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 11649170
[patent_doc_number] => 20170145071
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-25
[patent_title] => 'CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT'
[patent_app_type] => utility
[patent_app_number] => 15/340238
[patent_app_country] => US
[patent_app_date] => 2016-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 27015
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 27
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15340238
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/340238 | CD80 extracellular domain polypeptides and their use in cancer treatment | Oct 31, 2016 | Issued |
Array
(
[id] => 16548539
[patent_doc_number] => 10881677
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-05
[patent_title] => Composition for modulating IRAK1
[patent_app_type] => utility
[patent_app_number] => 15/770437
[patent_app_country] => US
[patent_app_date] => 2016-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 16256
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15770437
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/770437 | Composition for modulating IRAK1 | Oct 23, 2016 | Issued |
Array
(
[id] => 11434885
[patent_doc_number] => 20170035907
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-09
[patent_title] => 'METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB'
[patent_app_type] => utility
[patent_app_number] => 15/331700
[patent_app_country] => US
[patent_app_date] => 2016-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 19610
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331700
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/331700 | METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | Oct 20, 2016 | Abandoned |
Array
(
[id] => 15196311
[patent_doc_number] => 10495643
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-03
[patent_title] => Diagnostic methods for liver disorders
[patent_app_type] => utility
[patent_app_number] => 15/297833
[patent_app_country] => US
[patent_app_date] => 2016-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 20
[patent_no_of_words] => 8823
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 201
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15297833
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/297833 | Diagnostic methods for liver disorders | Oct 18, 2016 | Issued |
Array
(
[id] => 13958439
[patent_doc_number] => 20190055563
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-21
[patent_title] => POLYMERASE Q AS A TARGET IN HR-DEFICIENT CANCERS
[patent_app_type] => utility
[patent_app_number] => 15/768853
[patent_app_country] => US
[patent_app_date] => 2016-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19577
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768853
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/768853 | POLYMERASE Q AS A TARGET IN HR-DEFICIENT CANCERS | Oct 18, 2016 | Pending |
Array
(
[id] => 11568648
[patent_doc_number] => 20170107292
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-04-20
[patent_title] => 'ANTAGONISTS FOR ABDOMINAL VASOPRESSIN V2 RECEPTOR AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/291597
[patent_app_country] => US
[patent_app_date] => 2016-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 27345
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15291597
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/291597 | Antagonists for abdominal vasopressin V2 receptor and uses thereof | Oct 11, 2016 | Issued |
Array
(
[id] => 17171725
[patent_doc_number] => 20210325395
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => METHOD, ARRAY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/761966
[patent_app_country] => US
[patent_app_date] => 2016-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15761966
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/761966 | METHOD, ARRAY AND USE THEREOF | Sep 21, 2016 | Abandoned |
Array
(
[id] => 16061543
[patent_doc_number] => 10689707
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-23
[patent_title] => Treatment of recurrent gastric cancer identified using genetic biomarkers
[patent_app_type] => utility
[patent_app_number] => 15/252869
[patent_app_country] => US
[patent_app_date] => 2016-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 104
[patent_figures_cnt] => 104
[patent_no_of_words] => 14561
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 202
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15252869
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/252869 | Treatment of recurrent gastric cancer identified using genetic biomarkers | Aug 30, 2016 | Issued |
Array
(
[id] => 13659165
[patent_doc_number] => 10159726
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-12-25
[patent_title] => Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
[patent_app_type] => utility
[patent_app_number] => 15/249149
[patent_app_country] => US
[patent_app_date] => 2016-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 39
[patent_no_of_words] => 69803
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15249149
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/249149 | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | Aug 25, 2016 | Issued |
Array
(
[id] => 14516473
[patent_doc_number] => 10335471
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-07-02
[patent_title] => Method for treating cancer with activated T cells
[patent_app_type] => utility
[patent_app_number] => 15/249083
[patent_app_country] => US
[patent_app_date] => 2016-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 39
[patent_no_of_words] => 69838
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15249083
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/249083 | Method for treating cancer with activated T cells | Aug 25, 2016 | Issued |
Array
(
[id] => 11437365
[patent_doc_number] => 20170038385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-09
[patent_title] => 'G-Alpha Interacting Vesicle Associated Protein (GIV) as a Predictive Marker in Stage II Colorectal Cancer'
[patent_app_type] => utility
[patent_app_number] => 15/238662
[patent_app_country] => US
[patent_app_date] => 2016-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 34611
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15238662
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/238662 | G-Alpha Interacting Vesicle Associated Protein (GIV) as a Predictive Marker in Stage II Colorectal Cancer | Aug 15, 2016 | Abandoned |
Array
(
[id] => 13326045
[patent_doc_number] => 20180214560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-02
[patent_title] => HPMA-DRUG CONJUGATES FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
[patent_app_type] => utility
[patent_app_number] => 15/747413
[patent_app_country] => US
[patent_app_date] => 2016-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15747413
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/747413 | HPMA-DRUG CONJUGATES FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | Jul 21, 2016 | Abandoned |
Array
(
[id] => 12152868
[patent_doc_number] => 20180024133
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-25
[patent_title] => 'Methods for Detecting and for Treating Pancreatic Cancer'
[patent_app_type] => utility
[patent_app_number] => 15/216768
[patent_app_country] => US
[patent_app_date] => 2016-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 19575
[patent_no_of_claims] => 50
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15216768
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/216768 | Method of detecting the level of a glycan | Jul 21, 2016 | Issued |
Array
(
[id] => 11324992
[patent_doc_number] => 20160355604
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-08
[patent_title] => 'CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO'
[patent_app_type] => utility
[patent_app_number] => 15/206039
[patent_app_country] => US
[patent_app_date] => 2016-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 25466
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15206039
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/206039 | Cancer therapy using CLDN6 target-directed antibodies in vivo | Jul 7, 2016 | Issued |
Array
(
[id] => 13297637
[patent_doc_number] => 20180200355
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-19
[patent_title] => Immunogenic Preprocalcitonin Peptides
[patent_app_type] => utility
[patent_app_number] => 15/742771
[patent_app_country] => US
[patent_app_date] => 2016-07-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6224
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15742771
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/742771 | Immunogenic preprocalcitonin peptides | Jul 3, 2016 | Issued |
Array
(
[id] => 13026729
[patent_doc_number] => 10035981
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-07-31
[patent_title] => Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
[patent_app_type] => utility
[patent_app_number] => 15/200885
[patent_app_country] => US
[patent_app_date] => 2016-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 22
[patent_no_of_words] => 20857
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15200885
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/200885 | Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 | Jun 30, 2016 | Issued |
Array
(
[id] => 14031299
[patent_doc_number] => 10227388
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-12
[patent_title] => Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 15/199182
[patent_app_country] => US
[patent_app_date] => 2016-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 41
[patent_no_of_words] => 98079
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15199182
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/199182 | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | Jun 29, 2016 | Issued |
Array
(
[id] => 11436074
[patent_doc_number] => 20170037095
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-09
[patent_title] => 'Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers'
[patent_app_type] => utility
[patent_app_number] => 15/198853
[patent_app_country] => US
[patent_app_date] => 2016-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 105723
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15198853
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/198853 | Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide | Jun 29, 2016 | Issued |
Array
(
[id] => 11436076
[patent_doc_number] => 20170037096
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-09
[patent_title] => 'Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers'
[patent_app_type] => utility
[patent_app_number] => 15/199066
[patent_app_country] => US
[patent_app_date] => 2016-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 105770
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15199066
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/199066 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | Jun 29, 2016 | Issued |
Array
(
[id] => 12889234
[patent_doc_number] => 20180188253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-05
[patent_title] => Cancer Diagnostic
[patent_app_type] => utility
[patent_app_number] => 15/737457
[patent_app_country] => US
[patent_app_date] => 2016-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737457
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/737457 | Cancer Diagnostic | Jun 16, 2016 | Abandoned |